Cargando…

Real-World Effectiveness of Disease-Modifying Therapies in Korean Patients with Relapsing Multiple Sclerosis

BACKGROUND AND PURPOSE: This study assessed the long-term outcomes of disease-modifying therapies (DMTs) in Korean multiple sclerosis (MS) patients treated in real-world clinical settings in Korea. METHODS: We retrospectively evaluated the medical records of 160 patients with an initial diagnosis of...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Su-Hyun, Park, Min Su, Kim, Woojun, Huh, So-Young, Shin, Hyun-June, Hyun, Jae-Won, Kim, Ho Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Neurological Association 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325368/
https://www.ncbi.nlm.nih.gov/pubmed/30375760
http://dx.doi.org/10.3988/jcn.2019.15.1.20
_version_ 1783386116260364288
author Kim, Su-Hyun
Park, Min Su
Kim, Woojun
Huh, So-Young
Shin, Hyun-June
Hyun, Jae-Won
Kim, Ho Jin
author_facet Kim, Su-Hyun
Park, Min Su
Kim, Woojun
Huh, So-Young
Shin, Hyun-June
Hyun, Jae-Won
Kim, Ho Jin
author_sort Kim, Su-Hyun
collection PubMed
description BACKGROUND AND PURPOSE: This study assessed the long-term outcomes of disease-modifying therapies (DMTs) in Korean multiple sclerosis (MS) patients treated in real-world clinical settings in Korea. METHODS: We retrospectively evaluated the medical records of 160 patients with an initial diagnosis of clinically isolated syndrome or relapsing-remitting MS who were treated for at least 2 years. A status of 3 for no evidence of disease activity (NEDA3) was defined as no relapse, disability progression, or active lesions in annual magnetic resonance imaging (MRI) evaluations. RESULTS: Patients who were initially treated with interferon β (n=152), glatiramer acetate (n=6), or teriflunomide (n=2) were included. The mean disease duration was 8.2 years. Compared to pretreatment, annualized relapse rates were significantly reduced after treatment [from 1.0±0.8 to 0.2±0.4 (mean±standard deviation), p<0.001]. At the follow-up, 79 patients (49%) had changed their treatment regimen due to lack of efficacy (33%), side effects (14%), or other reasons (2%). Disability progression was observed in 18% of the patients over a mean treatment duration of 5.7 years. After 2 years, NEDA3 was observed in 38% of the patients. Loss of NEDA3 at 2 years was associated with long-term disability progression [odds ratio (OR)=17.975, p=0.003]. Poor response to first-line treatment was independently associated with a delay in treatment from disease onset (OR=1.238, p=0.049) and 10 or more brain lesions in the initial MRI (OR=3.648, p=0.047). CONCLUSIONS: This study has provided real-world evidence that DMTs are effective in reducing disease activity and disability progression in Korean MS patients.
format Online
Article
Text
id pubmed-6325368
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Korean Neurological Association
record_format MEDLINE/PubMed
spelling pubmed-63253682019-01-11 Real-World Effectiveness of Disease-Modifying Therapies in Korean Patients with Relapsing Multiple Sclerosis Kim, Su-Hyun Park, Min Su Kim, Woojun Huh, So-Young Shin, Hyun-June Hyun, Jae-Won Kim, Ho Jin J Clin Neurol Original Article BACKGROUND AND PURPOSE: This study assessed the long-term outcomes of disease-modifying therapies (DMTs) in Korean multiple sclerosis (MS) patients treated in real-world clinical settings in Korea. METHODS: We retrospectively evaluated the medical records of 160 patients with an initial diagnosis of clinically isolated syndrome or relapsing-remitting MS who were treated for at least 2 years. A status of 3 for no evidence of disease activity (NEDA3) was defined as no relapse, disability progression, or active lesions in annual magnetic resonance imaging (MRI) evaluations. RESULTS: Patients who were initially treated with interferon β (n=152), glatiramer acetate (n=6), or teriflunomide (n=2) were included. The mean disease duration was 8.2 years. Compared to pretreatment, annualized relapse rates were significantly reduced after treatment [from 1.0±0.8 to 0.2±0.4 (mean±standard deviation), p<0.001]. At the follow-up, 79 patients (49%) had changed their treatment regimen due to lack of efficacy (33%), side effects (14%), or other reasons (2%). Disability progression was observed in 18% of the patients over a mean treatment duration of 5.7 years. After 2 years, NEDA3 was observed in 38% of the patients. Loss of NEDA3 at 2 years was associated with long-term disability progression [odds ratio (OR)=17.975, p=0.003]. Poor response to first-line treatment was independently associated with a delay in treatment from disease onset (OR=1.238, p=0.049) and 10 or more brain lesions in the initial MRI (OR=3.648, p=0.047). CONCLUSIONS: This study has provided real-world evidence that DMTs are effective in reducing disease activity and disability progression in Korean MS patients. Korean Neurological Association 2019-01 2018-10-26 /pmc/articles/PMC6325368/ /pubmed/30375760 http://dx.doi.org/10.3988/jcn.2019.15.1.20 Text en Copyright © 2019 Korean Neurological Association http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Kim, Su-Hyun
Park, Min Su
Kim, Woojun
Huh, So-Young
Shin, Hyun-June
Hyun, Jae-Won
Kim, Ho Jin
Real-World Effectiveness of Disease-Modifying Therapies in Korean Patients with Relapsing Multiple Sclerosis
title Real-World Effectiveness of Disease-Modifying Therapies in Korean Patients with Relapsing Multiple Sclerosis
title_full Real-World Effectiveness of Disease-Modifying Therapies in Korean Patients with Relapsing Multiple Sclerosis
title_fullStr Real-World Effectiveness of Disease-Modifying Therapies in Korean Patients with Relapsing Multiple Sclerosis
title_full_unstemmed Real-World Effectiveness of Disease-Modifying Therapies in Korean Patients with Relapsing Multiple Sclerosis
title_short Real-World Effectiveness of Disease-Modifying Therapies in Korean Patients with Relapsing Multiple Sclerosis
title_sort real-world effectiveness of disease-modifying therapies in korean patients with relapsing multiple sclerosis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325368/
https://www.ncbi.nlm.nih.gov/pubmed/30375760
http://dx.doi.org/10.3988/jcn.2019.15.1.20
work_keys_str_mv AT kimsuhyun realworldeffectivenessofdiseasemodifyingtherapiesinkoreanpatientswithrelapsingmultiplesclerosis
AT parkminsu realworldeffectivenessofdiseasemodifyingtherapiesinkoreanpatientswithrelapsingmultiplesclerosis
AT kimwoojun realworldeffectivenessofdiseasemodifyingtherapiesinkoreanpatientswithrelapsingmultiplesclerosis
AT huhsoyoung realworldeffectivenessofdiseasemodifyingtherapiesinkoreanpatientswithrelapsingmultiplesclerosis
AT shinhyunjune realworldeffectivenessofdiseasemodifyingtherapiesinkoreanpatientswithrelapsingmultiplesclerosis
AT hyunjaewon realworldeffectivenessofdiseasemodifyingtherapiesinkoreanpatientswithrelapsingmultiplesclerosis
AT kimhojin realworldeffectivenessofdiseasemodifyingtherapiesinkoreanpatientswithrelapsingmultiplesclerosis